A team of researchers has discovered that a hormone made by a small gland in the brain may treat blood cancers such as leukemia and lymphoma.
According to researchers, melatonin, a hormone made by a small gland in the brain, may treat blood cancers such as leukemia and lymphoma.
The findings suggested that melatonin boosts the immune response against cancer cells, inhibits cancer cell growth and protects healthy cells from the toxic effects of chemotherapy.
Melatonin is also involved in regulating circadian rhythms, which may help coordinate and synchronise internal body functions, timing of melatonin treatments may be critical to their anti-cancer effects.
Senior author Yang Yang stated that they hope this information will be helpful in the design of studies related to the therapeutic efficacy of melatonin in blood cancers.
Melatonin's anti-cancer actions will help facilitate future basic research and clinical applications, the researchers noted.
The study appears in British Journal of Pharmacology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
